Sun Pharmaceutical Industries November 09, 2012 Sun Pharma’s Q2FY13 core performance was in line with the estimates, while reported performance was impacted by one-time provision related to Protonix litigation. T - Financial core - Document - PDFSEARCH.IO

First Page	Meta Content
	Sun Pharmaceutical Industries November 09, 2012 Sun Pharma’s Q2FY13 core performance was in line with the estimates, while reported performance was impacted by one-time provision related to Protonix litigation. T Add to Reading List Document Date: 2012-11-17 02:22:43 Open Document File Size: 185,27 KB Share Result on Facebook Company PL Research Prabhudas Lilladher Pvt. Ltd. / DUSA Pharma / Financing Inc. / 3M / Sun Pharma / / Country United States / India / / Currency USD / Rs / / / Event Earnings Guidance / M&A / / IndustryTerm pharmaceuticals / exclusivity product / / Person Taro / Amit Shah / / / Technology API / / SocialTag Earnings before interest, taxes, depreciation and amortization Financial ratio Income Profit Pharmaceutical industry in India Net profit BSE SENSEX Pharmaceutical industry Revenue Generally Accepted Accounting Principles

Sun Pharmaceutical Industries November 09, 2012 Sun Pharma’s Q2FY13 core performance was in line with the estimates, while reported performance was impacted by one-time provision related to Protonix litigation. TAdd to Reading List